Cécile Réal

Cécile is an experienced entrepreneur in the medical industry and the management of startups. She co-founded her first startup at the age of 25: Bioprofile, developing innovative solutions for arthritis. She rapidly expanded the company and gained strong experience in product development, business development and fundraising. She also set up an international distribution network and integrated Bioprofile within a US SME, before being acquired by a larger company. She then co-founded Fluoptics and served as Interim CEO at Inatherys, two startups developing imaging solutions and a new drug to treat cancer. 

In 2011, Cecile co-founded Endodiag, specializing in endometriosis diagnosis, and Medevice Capital, an entrepreneur seed fund specializing in medical devices. She is passionate about innovation, impact and entrepreneurship, and dedicates part of her time to mentor women entrepreneurs.

Cécile has been nominated Women Entrepreneur of the Year by France Biotech (2016), EU Women entrepreneur by the European Commission (2016) and jury President of the Ilab competition 2022 (French National Innovation competition). Endodiag is an innovative biotechnology company fully dedicated to the development of new solutions to improve the diagnosis of endometriosis. Endometriosis is a disease that causes unbearable pain and infertility and affects 180 million women worldwide. Medevice Capital is a seed fund dedicated to medical devices and e-health.

Medevice Capital is driven by entrepreneurs, invests in early-stage company and actively helps them to grow. Medevice's motto is “Smart ideas for big impact”.